Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after nearly four years at the helm.
His last day will be Dec. 31, Roche said, as Anderson leaves to “pursue opportunities outside of Roche.” A successor will be appointed by March, the company added.
Anderson’s departure comes at the end of a rocky year for the Swiss drugmaker. The company watched two of its most closely watched candidates fail to yield results in late-stage trials: An experimental amyloid-clearing antibody failed to slow Alzheimer’s patients’ cognitive decline, and an experimental antibody for a new, highly anticipated, immuno-oncology target called TIGIT failed to slow tumor growth in two different cancers.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
